EP 213: Inside the science of hearing loss and gene therapy for deafness with Ellen Reisinger

Value of the Information & Strength of the Argument

The value of the information is high, as it provides an in-depth, expert perspective on the current state and future of gene therapy for hearing loss. Dr. Reisinger offers detailed explanations of the scientific mechanisms, such as the dual AAV system and the rationale for targeting otoferlin, which are not commonly found in general media. The argumentation is solid, grounded in her research experience and the broader scientific literature. She presents balanced views, acknowledging limitations and uncertainties, such as the challenges with GJB2 and the risks of prenatal therapy. The discussion is well-structured, moving from basic science to clinical applications and future directions, making it valuable for both specialists and informed laypersons.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, as Dr. Reisinger is a leading expert in the field, and her statements align with published research. The quality of sources is implicit, as she references her own work and known studies, but no specific citations are provided in the video. The title accurately reflects the content, which focuses on the science of hearing loss and gene therapy. The episode is part of a reputable podcast series, adding to its credibility. No comments were provided for analysis.

The title accurately reflects the content, which focuses on the science of hearing loss and gene therapy, with Ellen Reisinger as the guest expert.

8/10

The content is an expert interview with a leading researcher in gene therapy for hearing loss. The information is based on her extensive research and published work. The discussion is scientifically accurate and well-contextualized, with appropriate caveats about current limitations. However, as an opinion piece, it lacks peer review and some claims are forward-looking.

• 00:00Intro to The Genetics Podcast
• 00:59Welcome to Ellen
• 01:52Ellen’s career path that coincidentally led to her work on otoferlin-related hearing loss
• 03:22Mechanism and advantages of the dual adenoassociated virus (AAV) system
• 05:35The genetic landscape of early-onset hearing loss and why otoferlin stands out
• 07:42Why otoferlin-related deafness is an ideal target for postnatal gene therapy development
• 09:53Potential next gene therapy targets beyond otoferlin and associated challenges
• 13:13Carrier and newborn screening as approaches to preventing hereditary hearing loss
• 14:37How far the field is from prenatal gene therapy and why it remains unlikely in the near term
• 16:07Exploring gene-agnostic and protective approaches to prevent or slow hearing loss
• 18:22How genetics and environment interact in age-related hearing loss
• 20:00Current research focus of Ellen’s group on degenerative hearing loss genes and uncovering cell death mechanisms
• 22:05Using mouse models and human organoids to study hearing loss mechanisms
• 23:42Emerging gene editing approaches
• 25:20Ellen’s research journey from biochemistry to leading gene therapy research in hearing loss
• 27:54Unanswered questions about how inner hair cells release neurotransmitters
• 29:21Comparing outcomes of gene therapy and cochlear implants for hearing restoration and differences across languages
• 34:20Closing remarks

• Show Notes and Transcript — The show notes provide a detailed outline of the episode, including timestamps and topics discussed.

• Otoferlin gene therapy in a mouse model — This study demonstrates the efficacy of dual AAV-mediated otoferlin gene therapy in mice, supporting the approach discussed in the episode.
• AAV vectors for gene therapy — This review provides background on AAV vectors, including their cargo capacity and use in clinical trials, relevant to the dual AAV system explained.